Item 8.01 Other Events.

On May 26, 2022, eFFECTOR Therapeutics, Inc. (the "Company" or "our") announced that the interim data from its ongoing Phase 1/2 clinical trial of zotatifin in solid tumors demonstrated that the recommended Phase 2 dose (RP2D) of zotatifin was well-tolerated and achieved pharmacologically active exposures as shown by reductions in target proteins in on-treatment biopsies and two responses as of the most recent data cut-off in the expansion cohorts.

Forward-Looking Statements

eFFECTOR cautions you that statements contained in this current report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the potential therapeutic benefits of our product candidates. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and more patient data become available; and other risks described in our prior filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses